VTR Stock Recent News

Ventas had a solid Q1-2023, with SHOP NOI expanding by 17%. The FFO though declined, and we explain why. We think SHOP will do well over the next 12 months as occupancies rise.

A rise in healthcare spending by senior citizens, accretive investments in the R&I business and office segment, and a solid balance sheet imply an optimistic near-term scenario for Ventas (VTR).

Ventas (VTR) reported earnings 30 days ago. What's next for the stock?

Ventas, Inc. (NYSE:VTR ) The Nareit REITweek 2023 Investor Conference Call June 6, 2023 2:15 PM ET Company Participants BJ Grant - Senior Vice President, Investor Relations Debra Cafaro - Chairman and Chief Executive Officer Justin Hutchens - Executive Vice President, Senior Housing and Chief Investment Officer Bob Probst - Executive Vice President and Chief Financial Officer Conference Call Participants Jon Peterson - Jefferies Jon Peterson Alright, we'll start a few seconds early. I think that's okay.

CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) announced today that management will make a presentation regarding the Company at Nareit's REITweek 2023 Investor Conference (the “Nareit Conference”) on June 6, 2023 at 2:15 p.m. Eastern Time. The webcast will be accessible on the Company's website at ir.ventasreit.com/events-and-presentations. Any Company written materials accompanying the participation at the Nareit Conference will be available on the Company's we.

Ventas (VTR) stands to gain from a diverse healthcare real estate portfolio, rebounding senior housing market and biopharma opportunities. Yet, tenant concentration and high interest rates remain concerns.

Ventas's (VTR) Q1 earnings outshine estimates on better-than-anticipated revenues. The SHOP same-store cash NOI improves on strong pricing power and margin expansion.

While the top- and bottom-line numbers for Ventas (VTR) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ventas' (VTR) Q1 earnings are likely to have benefited from the positive operating trends of its senior housing operating portfolio and high demand for life-science real-estate assets.

Several analysts following Ventas trimmed their price targets while maintaining their outperform ratings. They believe the Santerre transaction will be a near-term headwind.